Cimoli G - Search Results

1

Meta-analysis of the role of p53 status in isogenic systems tested for sensitivity to cytotoxic antineoplastic drugs.

Cimoli G, Malacarne D, Ponassi R, Valenti M, Alberti S, Parodi S. Cimoli G, et al. Biochim Biophys Acta. 2004 Dec 17;1705(2):103-20. doi: 10.1016/j.bbcan.2004.10.001. Biochim Biophys Acta. 2004. PMID: 15588765 Review.

2

HPV16-E6 enhances mitoxantrone sensitivity in a human ovarian cancer line: an isolated instance or a trend?

Cimoli G, Valenti M, Ottoboni C, Parodi S. Cimoli G, et al. Int J Oncol. 2001 Apr;18(4):759-65. doi: 10.3892/ijo.18.4.759. Int J Oncol. 2001. PMID: 11251171

3

A novel Bim-BH3-derived Bcl-XL inhibitor: biochemical characterization, in vitro, in vivo and ex-vivo anti-leukemic activity.

Ponassi R, Biasotti B, Tomati V, Bruno S, Poggi A, Malacarne D, Cimoli G, Salis A, Pozzi S, Miglino M, Damonte G, Cozzini P, Spyrakis F, Campanini B, Bagnasco L, Castagnino N, Tortolina L, Mumot A, Frassoni F, Daga A, Cilli M, Piccardi F, Monfardini I, Perugini M, Zoppoli G, D'Arrigo C, Pesenti R, Parodi S. Ponassi R, et al. Among authors: cimoli g. Cell Cycle. 2008 Oct;7(20):3211-24. doi: 10.4161/cc.7.20.6830. Epub 2008 Oct 20. Cell Cycle. 2008. PMID: 18843207

4

Interactions between taxol and camptothecin.

Debernardis D, Cimoli G, Parodi S, Russo P. Debernardis D, et al. Among authors: cimoli g. Anticancer Drugs. 1996 Jul;7(5):531-4. doi: 10.1097/00001813-199607000-00007. Anticancer Drugs. 1996. PMID: 8862720

5

"Atypical" multidrug resistance in human ovarian cancer cell line A2780 selected for resistance to doxorubicin (A2780 DX3).

Cimoli G, Valenti M, Noviello E, Parodi S, Mazzoni A, Rovini E, De Sessa F, Russo P. Cimoli G, et al. J Cancer Res Clin Oncol. 1995;121(3):155-63. doi: 10.1007/BF01198097. J Cancer Res Clin Oncol. 1995. PMID: 7713987

6

Reversal of "atypical"-multidrug resistance by recombinant human tumor necrosis factor in the human ovarian cancer cell line A2780-DX3.

Cimoli G, Valenti M, Parodi S, Mazzoni A, De Sessa F, Conte P, Russo P. Cimoli G, et al. Oncol Res. 1993;5(8):311-23. Oncol Res. 1993. PMID: 8012063

7

Potentiation of tumour necrosis factor-mediated cell killing by VP16 on human ovarian cancer cell lines. In vitro results and clinical implications.

Valenti M, Cimoli G, Parodi S, Mariani GL, Venturini M, Conte P, Russo P. Valenti M, et al. Among authors: cimoli g. Eur J Cancer. 1993;29A(8):1157-61. doi: 10.1016/s0959-8049(05)80307-7. Eur J Cancer. 1993. PMID: 8518027

8

Sister-chromatid exchanges, chromosomal aberrations and cytotoxicity produced by topoisomerase II-targeted drugs in sensitive (A2780) and resistant (A2780-DX3) human ovarian cancer cells: correlations with the formation of DNA double-strand breaks.

Noviello E, Aluigi MG, Cimoli G, Rovini E, Mazzoni A, Parodi S, De Sessa F, Russo P. Noviello E, et al. Among authors: cimoli g. Mutat Res. 1994 Nov 1;311(1):21-9. doi: 10.1016/0027-5107(94)90069-8. Mutat Res. 1994. PMID: 7526171

9

Circumvention of atypical multidrug resistance with tumor necrosis factor.

Cimoli G, Valenti M, Parodi S, De Sessa F, Russo P. Cimoli G, et al. Jpn J Cancer Res. 1994 Feb;85(2):135-8. doi: 10.1111/j.1349-7006.1994.tb02073.x. Jpn J Cancer Res. 1994. PMID: 8144394 Free PMC article.

10

Potentiation of TNF-mediated cell killing by mitoxantrone. Relationship to DNA single-strand break formation.

Valenti M, Cimoli G, Mariani GL, Conte PF, Parodi S, Russo P. Valenti M, et al. Among authors: cimoli g. Biochem Pharmacol. 1993 Oct 5;46(7):1199-206. doi: 10.1016/0006-2952(93)90468-c. Biochem Pharmacol. 1993. PMID: 8216370

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

30 results

Search Page